Oncolytics Biotech
Market Cap
CA$144.6m
Last Updated
2020/11/26 23:12 UTC
Data Sources
Company Financials +
Executive Summary
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. More Details
Snowflake Analysis
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Oncolytics Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ONC is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ONC's weekly volatility has decreased from 19% to 9% over the past year.
Market Performance
7 Day Return
32.5%
ONC
4.9%
CA Biotechs
2.8%
CA Market
1 Year Return
134.0%
ONC
80.8%
CA Biotechs
-0.3%
CA Market
Return vs Industry: ONC exceeded the Canadian Biotechs industry which returned 76.8% over the past year.
Return vs Market: ONC exceeded the Canadian Market which returned -0.5% over the past year.
Shareholder returns
| ONC | Industry | Market | |
|---|---|---|---|
| 7 Day | 32.5% | 4.9% | 2.8% |
| 30 Day | 17.8% | 24.7% | 10.0% |
| 90 Day | 53.3% | 25.8% | 5.7% |
| 1 Year | 134.0%134.0% | 80.8%80.8% | 3.3%-0.3% |
| 3 Year | -47.2%-47.2% | 18.5%18.5% | 12.2%1.3% |
| 5 Year | -4.0%-4.0% | 6.0%6.0% | 49.1%26.2% |
Long-Term Price Volatility Vs. Market
How volatile is Oncolytics Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully5 months ago | Simply Wall St
Does Oncolytics Biotech Inc. (TSE:ONC) Have A Volatile Share Price?6 months ago | Simply Wall St
How Much Are Oncolytics Biotech Inc. (TSE:ONC) Insiders Spending On Buying Shares?Valuation
Is Oncolytics Biotech undervalued compared to its fair value and its price relative to the market?
7.09x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ONC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ONC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ONC is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: ONC is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ONC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ONC is overvalued based on its PB Ratio (7.1x) compared to the CA Biotechs industry average (6.2x).
Next Steps
Future Growth
How is Oncolytics Biotech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
67.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: ONC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ONC's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if ONC's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: Insufficient data to determine if ONC's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ONC's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Oncolytics Biotech performed over the past 5 years?
-17.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ONC is currently unprofitable.
Growing Profit Margin: ONC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ONC is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare ONC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).
Return on Equity
High ROE: ONC has a negative Return on Equity (-155.35%), as it is currently unprofitable.
Next Steps
Financial Health
How is Oncolytics Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: ONC's short term assets (CA$30.5M) exceed its short term liabilities (CA$3.4M).
Long Term Liabilities: ONC's short term assets (CA$30.5M) exceed its long term liabilities (CA$6.9M).
Debt to Equity History and Analysis
Debt Level: ONC is debt free.
Reducing Debt: ONC had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ONC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ONC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2.4% each year
Next Steps
Dividend
What is Oncolytics Biotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ONC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ONC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ONC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.7yrs
Average management tenure
CEO
Matt Coffey
3.83yrs
Tenure
CA$964,677
Compensation
Dr. Matthew C. Coffey, also known as Matt, Ph.D.,M.B.A., Co-founded Oncolytics Biotech Inc., and has been its Chief Executive Officer and President since January 19, 2017. Dr. Coffey served as Interim Chie...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD741.12K) is above average for companies of similar size in the Canadian market ($USD166.12K).
Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.83yrs | CA$964.68k | 0.11% CA$ 160.1k | |
| Chief Financial Officer | 8yrs | CA$681.07k | 0.025% CA$ 36.5k | |
| Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc | no data | CA$634.43k | 0.024% CA$ 34.4k | |
| Consultant | 1.5yrs | CA$25.98k | no data | |
| Global Head of Clinical Development & Operations | 0.25yr | no data | no data | |
| Director of Investor Relations & Communication | no data | no data | no data | |
| Scientist of Translational Medicine | no data | no data | no data | |
| Consultant | no data | no data | no data |
2.7yrs
Average Tenure
Experienced Management: ONC's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.83yrs | CA$964.68k | 0.11% CA$ 160.1k | |
| Independent Director | 5.42yrs | CA$98.92k | 0.52% CA$ 753.3k | |
| Independent Director | 5.42yrs | CA$103.09k | 0.14% CA$ 199.7k | |
| Independent Director | 1.08yrs | CA$28.12k | no data | |
| Independent Chairman of the Board | 5.42yrs | CA$132.22k | 0.36% CA$ 514.9k | |
| Independent Director | 6.42yrs | CA$114.51k | 0.23% CA$ 327.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3yrs | CA$107.96k | 0.10% CA$ 144.5k | |
| Member of Scientific Advisory Board | 3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 0.083yr | no data | no data |
5.4yrs
Average Tenure
63yo
Average Age
Experienced Board: ONC's board of directors are considered experienced (5.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ONC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 64.3%.
Top Shareholders
Company Information
Oncolytics Biotech Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Oncolytics Biotech Inc.
- Ticker: ONC
- Exchange: TSX
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$144.618m
- Shares outstanding: 43.30m
- Website: https://www.oncolyticsbiotech.com
Location
- Oncolytics Biotech Inc.
- 1167 Kensington Crescent NW
- Suite 210
- Calgary
- Alberta
- T2N 1X7
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ONCY | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Nov 1999 |
| ONC | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Nov 1999 |
| ONYN | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Nov 1999 |
Biography
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an i...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/26 23:12 |
| End of Day Share Price | 2020/11/26 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.